#######################
# Document Properties #
#######################
SET DOCUMENT Copyright   = "Copyright © 2019 Fraunhofer Institute SCAI, All rights reserved."
SET DOCUMENT Licenses    = "CC BY 4.0"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"

SET DOCUMENT Name        = "Oxidative stress in health and disease: The therapeutic potential of Nrf2 activation"
SET DOCUMENT Version     = "1.0.0"
SET DOCUMENT Authors     = "Sandra Spalek"
SET DOCUMENT Description = ""

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/terminology
# --------------------------------------------------------------
DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns"
DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns"
DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns"
# DEFINE NAMESPACE FB           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/80171ae62cf43aa1fc8a6c326b94537ab342458c/external/fb-names.belns"
DEFINE NAMESPACE HBP            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/cfd2ee89d1a71126da8b5f452544b7fe43be67e7/export/hbp-names.belns"
DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns"
DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/terminology/73688d6dc24e309fca59a1340dc9ee971e9f3baa/external/hgnc.genefamily-names.belns"
DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/a5b84013a08880975ca84f40999e4404b14a97e2/external/go-names.belns"
DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns"
DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/01c9daa61012b37dd0a1bc962521ba51a15b38f1/external/mesh-names.belns"
DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns"
DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns"
DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns"
DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns"

# Namespaces hosted on https://arty.scai.fraunhofer.de/artifactory/bel/namespace
# ------------------------------------------------------------------------------
DEFINE NAMESPACE HP             AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns"

# Namespaces defined with regular expressions
# -------------------------------------------
DEFINE NAMESPACE DBSNP          AS PATTERN "rs[0-9]+"
DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
DEFINE NAMESPACE UNIPROT        AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
DEFINE NAMESPACE PUBCHEM        AS PATTERN "^\d+$"

###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------
DEFINE ANNOTATION Species       AS PATTERN "^\d+$"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"

##############
# Statements #
##############

# Add statements below this comment

SET Citation = {"PubMed","22020111"}

SET Evidence = "Sulforaphane is often considered a ‘‘gold standard’’ among naturally-occurring
Nrf2 activators (Agyeman et al., 2011)."
a(CHEBI:sulforaphane) -> act(p(HGNC:NFE2L2))

SET Evidence = "The greatest FImax was observed with Protandim at 135-fold, followed by bardoxolone methyl at 67-fold, dimethyl fumarate at
55-fold, and sulforaphane at 21-fold"
a(PUBCHEM:135316034) -> act(p(HGNC:NFE2L2))
a(PUBCHEM:400769) -> act(p(HGNC:NFE2L2))
a(CHEBI:"dimethyl fumarate") -> act(p(HGNC:NFE2L2))
a(CHEBI:sulforaphane) -> act(p(HGNC:NFE2L2))

SET Evidence = "Bardoxolone methyl appeared to produce a biphasic induction, producing
near maximal FI over a range of concentrations from less than 40 nM to 0.4 lM"
a(PUBCHEM:400769) -> act(p(HGNC:NFE2L2))

SET Evidence = "When compared contemporaneously in the AREc32-based assay, FImax observed was in
the order Protandim > bardoxolone methyl > dimethyl fumarate > sulforaphane."
a(PUBCHEM:135316034) -> act(p(HGNC:NFE2L2))
a(PUBCHEM:400769) -> act(p(HGNC:NFE2L2))
a(CHEBI:"dimethyl fumarate") -> act(p(HGNC:NFE2L2))
a(CHEBI:sulforaphane) -> act(p(HGNC:NFE2L2))

SET Evidence = "A recent laboratory study of dimethyl fumarate found that the compound activates Nrf2 in primary astrocytes, but not in
the C6 glioma-derived cell line (Wilms et al., 2010), demonstrating that different cells may respond quite differently to Nrf2
activators"
SET MeSHAnatomy = "Astrocytes"
a(CHEBI:"dimethyl fumarate") -> act(p(HGNC:NFE2L2))
UNSET MeSHAnatomy
SET CellLine = "C6 cell"
a(CHEBI:"dimethyl fumarate") cnc act(p(HGNC:NFE2L2))
UNSET CellLine

SET Evidence = "Sirtuin 1 (SIRT1) was shown to decrease acetylation of Nrf2, as well as Nrf2-dependent transcription."
p(HGNC:SIRT1) -| p(HGNC:NFE2L2,pmod(Ac))

SET Evidence = "In our gene expression data, SIRT1 was induced 1.75-fold by Protandim (p = 0.015)."
a(PUBCHEM:135316034) -> p(HGNC:SIRT1)

SET Evidence = "The study also found that resveratrol, a putative activator of SIRT1
(Howitz et al., 2003), inhibited Nrf2-dependent transcription, apparently contradicting earlier reports that resveratrol activates
Nrf2 (Chen et al., 2005; Ungvari et al., 2010)."
a(CHEBI:resveratrol) -> act(p(HGNC:SIRT1))
a(CHEBI:resveratrol) -| act(p(HGNC:NFE2L2))

SET Evidence = "SLC7A11, induced 76-fold, encodes a cystine/glutamate antiporter responsible for maintaining
extracellular glutamate in the brain, and for importing cystine necessary for glutathione synthesis (Albrecht et al., 2010)."
# upregulation of gene expression by Protandim
a(PUBCHEM:135316034) -> p(HGNC:SLC7A11)
SET MeSHAnatomy = "Brain"
p(HGNC:SLC7A11) reg bp(GO:"glutamate homeostasis")
p(HGNC:SLC7A11) -> tloc(a(CHEBI:cystine),fromLoc(GO:"extracellular region"),toLoc(GO:intracellular))
a(CHEBI:cystine) -> a(CHEBI:glutathione)
UNSET MeSHAnatomy

SET Evidence = "This antiporter was recently found to be decreased by repeated cocaine exposure, and restoration of the activity prevented
cocaine-primed drug seeking behavior in rats (Baker et al., 2003)."
#this antiporter: SLC7A11
a(CHEBI:cocaine) -| act(p(HGNC:SLC7A11))

SET Evidence = "AKR1B10, induced 72-fold, encodes aldo–keto reductase
family 1 member B10 which efficiently detoxifies mutagenic and carcinogenic alpha, beta-unsaturated carbonyls such as
4-hydroxynonenal (Zhong et al., 2009)."
# upregulation of gene expression by Protandim
a(PUBCHEM:135316034) -> p(HGNC:AKR1B10)
p(HGNC:AKR1B10) -> bp(GO:detoxification)
p(HGNC:AKR1B10) -| a(PUBCHEM:5283344)

SET Evidence = "PTGR1 (aka LTB4DH), induced 68-fold, encodes leukotriene B4-12-hydroxydehydrogenase,
which is considered to be a key enzyme responsible for biological inactivation of prostaglandins and related eicosanoids (Tai et al., 2002)."
# upregulation of gene expression by Protandim
a(PUBCHEM:135316034) -> p(HGNC:PTGR1)
p(HGNC:PTGR1) -| act(a(MESH:Prostaglandins))
p(HGNC:PTGR1) -| act(a(MESH:Eicosanoids))

SET Evidence = "HMOX1, induced 56-fold, encodes heme oxygenase-1, an antioxidant enzyme considered a hallmark of Nrf2 activation."
# upregulation of gene expression by Protandim
a(PUBCHEM:135316034) -> p(HGNC:HMOX1)
p(HGNC:HMOX1) -> act(p(HGNC:NFE2L2))

SET Evidence = "AIFM2 (aka AMID), induced 29-fold, is implicated in caspase-independent apoptosis
and was found to be downregulated in a majority of human tumors (Wu et al., 2004b)."
# upregulation of gene expression by Protandim
a(PUBCHEM:135316034) -> p(HGNC:AIFM2)
path(MESH:Neoplasms) neg p(HGNC:AIFM2)

SET Evidence = "OSGIN1 (aka OKL38), induced
29-fold, is an oxidative stress response gene and a tumor suppressor gene (Yao et al., 2008)."
# upregulation of gene expression by Protandim
a(PUBCHEM:135316034) -> p(HGNC:OSGIN1)

SET Evidence = "GPX3, induced 20-fold, encodes
an important antioxidant enzyme, glutathione peroxidase-3, found normally in plasma and kidney but underexpressed in
head and neck cancers (Chen et al., 2011)."
# upregulation of gene expression by Protandim
a(PUBCHEM:135316034) -> p(HGNC:GPX3)
SET MeSHAnatomy = {"Head","Neck"}
path(MESH:Neoplasms) neg p(HGNC:GPX3)
UNSET MeSHAnatomy

SET Evidence = "SQSTM1, induced 20-fold, encodes sequestosome-1, a participant in the autophagy
pathway recently shown to be necessary to avoid premature senescence in human fibroblasts (Kang et al., 2011)."
# upregulation of gene expression by Protandim
a(PUBCHEM:135316034) -> p(HGNC:SQSTM1)
p(HGNC:SQSTM1) -> bp(GO:autophagy)
SET MeSHAnatomy = "Fibroblasts"
p(HGNC:SQSTM1) -| bp(GO:"stress-induced premature senescence")
UNSET MeSHAnatomy

SET Evidence = "HSPB8, induced 19-fold, is a heat shock protein that forms a complex with BAG3 (also induced 1.43-fold)."
# upregulation of gene expression by Protandim
a(PUBCHEM:135316034) -> p(HGNC:HSPB8)
p(HGNC:HSPB8) -> complex(p(HGNC:HSPB8),p(HGNC:BAG3))

SET Evidence = "Overexpression of the HSPB8-BAG3 complex also stimulates autophagy and facilitates
the clearance of mutated aggregation-prone proteins, the
accumulation of which characterizes many neurodegenerative disorders such as Alzheimer disease, Parkinson disease,
and amyotrophic lateral sclerosis (Seidel et al., 2011)."
complex(p(HGNC:HSPB8),p(HGNC:BAG3)) pos bp(GO:autophagy)
complex(p(HGNC:HSPB8),p(HGNC:BAG3)) -> deg(a(HBP:"protein aggregates"))
path(MESH:"Alzheimer Disease") pos a(HBP:"protein aggregates")
path(MESH:"Parkinson Disease") pos a(HBP:"protein aggregates")
path(MESH:"Amyotrophic Lateral Sclerosis") pos a(HBP:"protein aggregates")

SET Evidence = "TNFSF9 (aka CD137L), induced 19-fold, can induce maturation of human
immature monocyte-derived dendritic cells leading to an enhanced capacity of the dendritic cells to stimulate protective
T cell responses, as compared to classical dendritic cells (Tang et al., 2011)."
# upregulation of gene expression by Protandim
a(PUBCHEM:135316034) -> p(HGNC:TNFSF9)
p(HGNC:TNFSF9) -> act(a(MESH:"Dendritic Cells"))
act(a(MESH:"Dendritic Cells")) -> bp(GO:"T cell activation")
p(HGNC:TNFSF9) -> bp(GO:"T cell activation")

SET Evidence = "For example, 19 genes products have been associated
with atherosclerosis and are up or down-regulated by Protandim. Of these 19 genes, the first 16 listed (84%) were regulated
by Protandim in the opposing direction to that taken by the atherosclerosis disease process. The probable benefit of this effect
of Protandim is further supported by the fact that of the 11 gene products currently being targeted by drug interventions
(Table 1, in bold type), nine of them (Table 1, marked by asterisks) are modulated by Protandim in the same direction that is
proposed to be beneficial and caused by the therapeutic intervention."
path(MESH:Atherosclerosis) -> p(HGNC:CTNNB1)
path(MESH:Atherosclerosis) -> p(HGNC:DHFR)
path(MESH:Atherosclerosis) -> p(HGNC:EDN1)
path(MESH:Atherosclerosis) -> p(HGNC:ITGB3)
path(MESH:Atherosclerosis) -> p(HGNC:MKI67)
path(MESH:Atherosclerosis) -> p(HGNC:MMP11)
path(MESH:Atherosclerosis) -> p(HGNC:MMP14)
path(MESH:Atherosclerosis) -> p(HGNC:MMP2)
path(MESH:Atherosclerosis) -> p(HGNC:PDE7A)
path(MESH:Atherosclerosis) -> p(HGNC:PDE7B)
path(MESH:Atherosclerosis) -> p(HGNC:PLAU)
path(MESH:Atherosclerosis) -> p(HGNC:PTGS1)
path(MESH:Atherosclerosis) -> p(HGNC:SCARB1)
path(MESH:Atherosclerosis) -> p(HGNC:TUBB3)
path(MESH:Atherosclerosis) -| p(HGNC:NR3C1)
path(MESH:Atherosclerosis) -| p(HGNC:PPARA)
path(MESH:Atherosclerosis) -> p(HGNC:EGR1)
path(MESH:Atherosclerosis) -> p(HGNC:PTGS2)
path(MESH:Atherosclerosis) -> p(HGNC:SOAT1)
SET MeSHDisease = "Atherosclerosis"
a(PUBCHEM:135316034) -| p(HGNC:CTNNB1)
a(PUBCHEM:135316034) -| p(HGNC:DHFR)
a(PUBCHEM:135316034) -| p(HGNC:EDN1)
a(PUBCHEM:135316034) -| p(HGNC:ITGB3)
a(PUBCHEM:135316034) -| p(HGNC:MKI67)
a(PUBCHEM:135316034) -| p(HGNC:MMP11)
a(PUBCHEM:135316034) -| p(HGNC:MMP14)
a(PUBCHEM:135316034) -| p(HGNC:MMP2)
a(PUBCHEM:135316034) -| p(HGNC:PDE7A)
a(PUBCHEM:135316034) -| p(HGNC:PDE7B)
a(PUBCHEM:135316034) -| p(HGNC:PLAU)
a(PUBCHEM:135316034) -| p(HGNC:PTGS1)
a(PUBCHEM:135316034) -| p(HGNC:SCARB1)
a(PUBCHEM:135316034) -| p(HGNC:TUBB3)
a(PUBCHEM:135316034) -> p(HGNC:NR3C1)
a(PUBCHEM:135316034) -> p(HGNC:PPARA)
a(PUBCHEM:135316034) -> p(HGNC:EGR1)
a(PUBCHEM:135316034) -> p(HGNC:PTGS2)
a(PUBCHEM:135316034) -> p(HGNC:SOAT1)
UNSET MeSHDisease

SET Evidence = "In colon carcinoma, IPA analysis revealed 28 genes associated with the disease that were also modulated by Protandim
treatment. Of these, the first 25 listed (89%) were regulated by Protandim in the opposing direction to that taken by the colon
carcinoma disease process."
path(MESH:"Colorectal Neoplasms") -> p(HGNC:ACLY)
path(MESH:"Colorectal Neoplasms") -> p(HGNC:ANTXR1)
path(MESH:"Colorectal Neoplasms") -> p(HGNC:C20orf27)
path(MESH:"Colorectal Neoplasms") -> p(HGNC:CCNA2)
path(MESH:"Colorectal Neoplasms") -> p(HGNC:CHAF1A)
path(MESH:"Colorectal Neoplasms") -> p(HGNC:DHFR)
path(MESH:"Colorectal Neoplasms") -> p(HGNC:EFCAB11)
path(MESH:"Colorectal Neoplasms") -> p(HGNC:FEN1)
path(MESH:"Colorectal Neoplasms") -> p(HGNC:GINS2)
path(MESH:"Colorectal Neoplasms") -> p(HGNC:MCM10)
path(MESH:"Colorectal Neoplasms") -> p(HGNC:MCM4)
path(MESH:"Colorectal Neoplasms") -> p(HGNC:RNASEH2A)
path(MESH:"Colorectal Neoplasms") -> p(HGNC:SLIT2)
path(MESH:"Colorectal Neoplasms") -> p(HGNC:SPC25)
path(MESH:"Colorectal Neoplasms") -> p(HGNC:TFRC)
path(MESH:"Colorectal Neoplasms") -> p(HGNC:TK1)
path(MESH:"Colorectal Neoplasms") -> p(HGNC:TMEM97)
path(MESH:"Colorectal Neoplasms") -> p(HGNC:TRIP13)
path(MESH:"Colorectal Neoplasms") -> p(HGNC:TUBB)
path(MESH:"Colorectal Neoplasms") -> p(HGNC:TUBB3)
path(MESH:"Colorectal Neoplasms") -> p(HGNC:TYMS)
path(MESH:"Colorectal Neoplasms") -> p(HGNC:UBA1)
path(MESH:"Colorectal Neoplasms") -> p(HGNC:UNG)
path(MESH:"Colorectal Neoplasms") -> p(HGNC:VRK1)
path(MESH:"Colorectal Neoplasms") -| p(HGNC:ABCD3)
path(MESH:"Colorectal Neoplasms") -> p(HGNC:GLRX2)
path(MESH:"Colorectal Neoplasms") -> p(HGNC:MICB)
path(MESH:"Colorectal Neoplasms") -> p(HGNC:NQO1)
SET MeSHDisease = "Colorectal Neoplasms"
a(PUBCHEM:135316034) -| p(HGNC:ACLY)
a(PUBCHEM:135316034) -| p(HGNC:ANTXR1)
a(PUBCHEM:135316034) -| p(HGNC:C20orf27)
a(PUBCHEM:135316034) -| p(HGNC:CCNA2)
a(PUBCHEM:135316034) -| p(HGNC:CHAF1A)
a(PUBCHEM:135316034) -| p(HGNC:DHFR)
a(PUBCHEM:135316034) -| p(HGNC:EFCAB11)
a(PUBCHEM:135316034) -| p(HGNC:FEN1)
a(PUBCHEM:135316034) -| p(HGNC:GINS2)
a(PUBCHEM:135316034) -| p(HGNC:MCM10)
a(PUBCHEM:135316034) -| p(HGNC:MCM4)
a(PUBCHEM:135316034) -| p(HGNC:RNASEH2A)
a(PUBCHEM:135316034) -| p(HGNC:SLIT2)
a(PUBCHEM:135316034) -| p(HGNC:SPC25)
a(PUBCHEM:135316034) -| p(HGNC:TFRC)
a(PUBCHEM:135316034) -| p(HGNC:TK1)
a(PUBCHEM:135316034) -| p(HGNC:TMEM97)
a(PUBCHEM:135316034) -| p(HGNC:TRIP13)
a(PUBCHEM:135316034) -| p(HGNC:TUBB)
a(PUBCHEM:135316034) -| p(HGNC:TUBB3)
a(PUBCHEM:135316034) -| p(HGNC:TYMS)
a(PUBCHEM:135316034) -| p(HGNC:UBA1)
a(PUBCHEM:135316034) -| p(HGNC:UNG)
a(PUBCHEM:135316034) -| p(HGNC:VRK1)
a(PUBCHEM:135316034) -> p(HGNC:ABCD3)
a(PUBCHEM:135316034) -> p(HGNC:GLRX2)
a(PUBCHEM:135316034) -> p(HGNC:MICB)
a(PUBCHEM:135316034) -> p(HGNC:NQO1)
UNSET MeSHDisease

SET Evidence = "In addition, Protandim downregulated the one gene targeted by a chemotherapeutic drug, an
antimetabolite inhibitor for that gene’s product, thymidylate synthetase"
a(PUBCHEM:135316034) -| p(HGNC:TYMS)

SET Evidence = "In Alzheimer disease, 66 genes were identified that are also modulated by Protandim at the gene expression level. Of
these 66 genes, the first 43 of them (65%) were regulated by Protandim in the opposing direction to that taken by the Alzheimer
disease process. The beneficial effect of Protandim is further supported by the fact that of the 10 gene products currently
targeted by drug therapies, eight of them are modulated by Protandim in the same direction that is proposed to be
beneficial and caused by the drug."
path(MESH:"Alzheimer Disease") -> p(HGNC:AGRN)
path(MESH:"Alzheimer Disease") -> p(HGNC:ANP32A)
path(MESH:"Alzheimer Disease") -> p(HGNC:BAX)
path(MESH:"Alzheimer Disease") -> p(HGNC:BCHE)
path(MESH:"Alzheimer Disease") -> p(HGNC:BGN)
path(MESH:"Alzheimer Disease") -> p(HGNC:BRCA1)
path(MESH:"Alzheimer Disease") -> p(HGNC:CADPS2)
path(MESH:"Alzheimer Disease") -> p(HGNC:CAPN1)
path(MESH:"Alzheimer Disease") -> p(HGNC:CCNB1)
path(MESH:"Alzheimer Disease") -> p(HGNC:CDK1)
path(MESH:"Alzheimer Disease") -> p(HGNC:CDK2)
path(MESH:"Alzheimer Disease") -> p(HGNC:CDKN2A)
path(MESH:"Alzheimer Disease") -> p(HGNC:CXCR4)
path(MESH:"Alzheimer Disease") -> p(HGNC:EIF4EBP1)
path(MESH:"Alzheimer Disease") -> p(HGNC:FOLH1)
path(MESH:"Alzheimer Disease") -> p(HGNC:HOMER1)
path(MESH:"Alzheimer Disease") -> p(HGNC:HRH1)
path(MESH:"Alzheimer Disease") -> p(HGNC:IGF2)
path(MESH:"Alzheimer Disease") -> p(HGNC:IGFBP2)
path(MESH:"Alzheimer Disease") -> p(HGNC:LDLR)
path(MESH:"Alzheimer Disease") -> p(HGNC:MAOA)
path(MESH:"Alzheimer Disease") -> p(HGNC:NEFH)
path(MESH:"Alzheimer Disease") -> p(HGNC:NPDC1)
path(MESH:"Alzheimer Disease") -> p(HGNC:NRGN)
path(MESH:"Alzheimer Disease") -> p(HGNC:PREP)
path(MESH:"Alzheimer Disease") -> p(HGNC:PROS1)
path(MESH:"Alzheimer Disease") -> p(HGNC:PTGS1)
path(MESH:"Alzheimer Disease") -> p(HGNC:SELENBP1)
path(MESH:"Alzheimer Disease") -> p(HGNC:TAGLN)
path(MESH:"Alzheimer Disease") -> p(HGNC:TGFB1)
path(MESH:"Alzheimer Disease") -> p(HGNC:TUBB3)
path(MESH:"Alzheimer Disease") -> p(HGNC:VKORC1)
path(MESH:"Alzheimer Disease") -| p(HGNC:CANX)
path(MESH:"Alzheimer Disease") -| p(HGNC:GCNT2)
path(MESH:"Alzheimer Disease") -| p(HGNC:IDE)
path(MESH:"Alzheimer Disease") -| p(HGNC:MMP1)
path(MESH:"Alzheimer Disease") -| p(HGNC:NFE2L2)
path(MESH:"Alzheimer Disease") -| p(HGNC:NR3C1)
path(MESH:"Alzheimer Disease") -| p(HGNC:PPARA)
path(MESH:"Alzheimer Disease") -| p(HGNC:SLC6A6)
path(MESH:"Alzheimer Disease") -| p(HGNC:SYVN1)
path(MESH:"Alzheimer Disease") -| p(HGNC:TSHZ1)
path(MESH:"Alzheimer Disease") -| p(HGNC:TXN)
path(MESH:"Alzheimer Disease") -| p(HGNC:ACLY)
path(MESH:"Alzheimer Disease") -| p(HGNC:ATAD2)
path(MESH:"Alzheimer Disease") -| p(HGNC:BECN1)
path(MESH:"Alzheimer Disease") -| p(HGNC:DHCR24)
path(MESH:"Alzheimer Disease") -| p(HGNC:FGF2)
path(MESH:"Alzheimer Disease") -| p(HGNC:HTRA1)
path(MESH:"Alzheimer Disease") -| p(HGNC:PRKCE)
path(MESH:"Alzheimer Disease") -| p(HGNC:PRKDC)
path(MESH:"Alzheimer Disease") -| p(HGNC:SCD)
path(MESH:"Alzheimer Disease") -| p(HGNC:TUBB)
path(MESH:"Alzheimer Disease") -| p(HGNC:UNG)
path(MESH:"Alzheimer Disease") -> p(HGNC:ATP1A1)
path(MESH:"Alzheimer Disease") -> p(HGNC:CTSD)
path(MESH:"Alzheimer Disease") -> p(HGNC:GLRX)
path(MESH:"Alzheimer Disease") -> p(HGNC:HMOX1)
path(MESH:"Alzheimer Disease") -> p(HGNC:IL6R)
path(MESH:"Alzheimer Disease") -> p(HGNC:NPTX1)
path(MESH:"Alzheimer Disease") -> p(HGNC:NQO1)
path(MESH:"Alzheimer Disease") -> p(HGNC:PHF1)
path(MESH:"Alzheimer Disease") -> p(HGNC:PRKCD)
path(MESH:"Alzheimer Disease") -> p(HGNC:PTGS2)
path(MESH:"Alzheimer Disease") -> p(HGNC:RANBP9)
path(MESH:"Alzheimer Disease") -> p(HGNC:SOD1)
SET MeSHDisease = "Alzheimer Disease"
a(PUBCHEM:135316034) -| p(HGNC:AGRN)
a(PUBCHEM:135316034) -| p(HGNC:ANP32A)
a(PUBCHEM:135316034) -| p(HGNC:BAX)
a(PUBCHEM:135316034) -| p(HGNC:BCHE)
a(PUBCHEM:135316034) -| p(HGNC:BGN)
a(PUBCHEM:135316034) -| p(HGNC:BRCA1)
a(PUBCHEM:135316034) -| p(HGNC:CADPS2)
a(PUBCHEM:135316034) -| p(HGNC:CAPN1)
a(PUBCHEM:135316034) -| p(HGNC:CCNB1)
a(PUBCHEM:135316034) -| p(HGNC:CDK1)
a(PUBCHEM:135316034) -| p(HGNC:CDK2)
a(PUBCHEM:135316034) -| p(HGNC:CDKN2A)
a(PUBCHEM:135316034) -| p(HGNC:CXCR4)
a(PUBCHEM:135316034) -| p(HGNC:EIF4EBP1)
a(PUBCHEM:135316034) -| p(HGNC:FOLH1)
a(PUBCHEM:135316034) -| p(HGNC:HOMER1)
a(PUBCHEM:135316034) -| p(HGNC:HRH1)
a(PUBCHEM:135316034) -| p(HGNC:IGF2)
a(PUBCHEM:135316034) -| p(HGNC:IGFBP2)
a(PUBCHEM:135316034) -| p(HGNC:LDLR)
a(PUBCHEM:135316034) -| p(HGNC:MAOA)
a(PUBCHEM:135316034) -| p(HGNC:NEFH)
a(PUBCHEM:135316034) -| p(HGNC:NPDC1)
a(PUBCHEM:135316034) -| p(HGNC:NRGN)
a(PUBCHEM:135316034) -| p(HGNC:PREP)
a(PUBCHEM:135316034) -| p(HGNC:PROS1)
a(PUBCHEM:135316034) -| p(HGNC:PTGS1)
a(PUBCHEM:135316034) -| p(HGNC:SELENBP1)
a(PUBCHEM:135316034) -| p(HGNC:TAGLN)
a(PUBCHEM:135316034) -| p(HGNC:TGFB1)
a(PUBCHEM:135316034) -| p(HGNC:TUBB3)
a(PUBCHEM:135316034) -| p(HGNC:VKORC1)
a(PUBCHEM:135316034) -> p(HGNC:CANX)
a(PUBCHEM:135316034) -> p(HGNC:GCNT2)
a(PUBCHEM:135316034) -> p(HGNC:IDE)
a(PUBCHEM:135316034) -> p(HGNC:MMP1)
a(PUBCHEM:135316034) -> p(HGNC:NFE2L2)
a(PUBCHEM:135316034) -> p(HGNC:NR3C1)
a(PUBCHEM:135316034) -> p(HGNC:PPARA)
a(PUBCHEM:135316034) -> p(HGNC:SLC6A6)
a(PUBCHEM:135316034) -> p(HGNC:SYVN1)
a(PUBCHEM:135316034) -> p(HGNC:TSHZ1)
a(PUBCHEM:135316034) -> p(HGNC:TXN)
a(PUBCHEM:135316034) -| p(HGNC:ACLY)
a(PUBCHEM:135316034) -| p(HGNC:ATAD2)
a(PUBCHEM:135316034) -| p(HGNC:BECN1)
a(PUBCHEM:135316034) -| p(HGNC:DHCR24)
a(PUBCHEM:135316034) -| p(HGNC:FGF2)
a(PUBCHEM:135316034) -| p(HGNC:HTRA1)
a(PUBCHEM:135316034) -| p(HGNC:PRKCE)
a(PUBCHEM:135316034) -| p(HGNC:PRKDC)
a(PUBCHEM:135316034) -| p(HGNC:SCD)
a(PUBCHEM:135316034) -| p(HGNC:TUBB)
a(PUBCHEM:135316034) -| p(HGNC:UNG)
a(PUBCHEM:135316034) -> p(HGNC:ATP1A1)
a(PUBCHEM:135316034) -> p(HGNC:CTSD)
a(PUBCHEM:135316034) -> p(HGNC:GLRX)
a(PUBCHEM:135316034) -> p(HGNC:HMOX1)
a(PUBCHEM:135316034) -> p(HGNC:IL6R)
a(PUBCHEM:135316034) -> p(HGNC:NPTX1)
a(PUBCHEM:135316034) -> p(HGNC:NQO1)
a(PUBCHEM:135316034) -> p(HGNC:PHF1)
a(PUBCHEM:135316034) -> p(HGNC:PRKCD)
a(PUBCHEM:135316034) -> p(HGNC:PTGS2)
a(PUBCHEM:135316034) -> p(HGNC:RANBP9)
a(PUBCHEM:135316034) -> p(HGNC:SOD1)
UNSET MeSHDisease

SET Evidence = "A likely explanation for the increased expression of GLRX2 (glutaredoxin 2) and
NQO1 (NAD(P)H dehydrogenase, quinone 1) in colon carcinoma and of GLRX (glutaredoxin), HMOX1 (heme oxygenase-1),
NQO1, and SOD1 (superoxide dismutase 1) in Alzheimer is that it represents an adaptive attempt to partially compensate
for the increased level of oxidative stress associated with these diseases.
These antioxidant genes are also upregulated by Protandim, which would provide additional
antioxidant protection beyond that achieved by the ROS-dependent induction
of these enzymes in the diseased tissues."
path(MESH:"Colorectal Neoplasms") pos p(HGNC:GLRX2)
path(MESH:"Colorectal Neoplasms") pos p(HGNC:NQO1)
path(MESH:"Alzheimer Disease") pos p(HGNC:GLRX)
path(MESH:"Alzheimer Disease") pos p(HGNC:HMOX1)
path(MESH:"Alzheimer Disease") pos p(HGNC:NQO1)
path(MESH:"Alzheimer Disease") pos p(HGNC:SOD1)
path(MESH:"Colorectal Neoplasms") pos bp(MESH:"Oxidative Stress")
path(MESH:"Alzheimer Disease") pos bp(MESH:"Oxidative Stress")
SET MeSHDisease = "Colorectal Neoplasms"
a(PUBCHEM:135316034) -> p(HGNC:GLRX2)
a(PUBCHEM:135316034) -> p(HGNC:NQO1)
UNSET MeSHDisease
SET MeSHDisease = "Alzheimer Disease"
a(PUBCHEM:135316034) -> p(HGNC:GLRX)
a(PUBCHEM:135316034) -> p(HGNC:HMOX1)
a(PUBCHEM:135316034) -> p(HGNC:NQO1)
a(PUBCHEM:135316034) -> p(HGNC:SOD1)
UNSET MeSHDisease

SET Evidence = "While Protandim, bardoxolone methyl, BG-12, and sulforaphane all have been demonstrated to modify gene expression
profiles by activation of Nrf2, they have not been compared side by side, in the same cell line, under identical conditions."
a(PUBCHEM:135316034) -> act(p(HGNC:NFE2L2))
a(PUBCHEM:400769) -> act(p(HGNC:NFE2L2))
a(CHEBI:"dimethyl fumarate") -> act(p(HGNC:NFE2L2))
a(CHEBI:sulforaphane) -> act(p(HGNC:NFE2L2))

SET Evidence = "After 52 weeks, the estimated glomerular filtration rate in the 75 mg/day treatment
group had increased by 10.5 ± 1.8 ml/min/1.73 m2 (p < 0.001), representing an increase of about 32% when compared
to entry values."
# bardoxolone methyl therapy
a(PUBCHEM:400769) -> bp(GO:"glomerular filtration")

SET Evidence = "The study suggests that Nrf2 activation represents a viable new therapeutic approach for renal disease, as
similar results are not achievable with currently available therapies"
act(p(HGNC:NFE2L2)) neg path(MESH:"Kidney Diseases")

SET Evidence = "Patients with relapsing-remitting multiple sclerosis treated with BG-12 for 24 weeks showed significantly fewer new
gadolinium-enhancing lesions, with significantly reduced probability of their evolution to T1-hypointense lesions than patients
treated with placebo (Macmanus et al., 2011)"
a(PUBCHEM:400769) neg path(MESH:"Multiple Sclerosis, Relapsing-Remitting")

SET Evidence = "These studies suggest that Nrf2 activation may represent a promising new therapeutic approach for multiple sclerosis."
act(p(HGNC:NFE2L2)) neg path(MESH:"Multiple Sclerosis, Relapsing-Remitting")
